Long-term treatment with potent compounds (BIBF-1120, nintedanib) that inhibiting various pro-angiogenic factors (VEGF, FGF and PDGF) resulted in a striking impairment in the number of immature B lymphocytes in the blood from tumor-bearing mice as well as prominent reductions in tumor volume and microvascular density. This evidence concerns the gene VEGFA and neoplasm.